MedTrace Logo

Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure

NCT05705869 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 706

Last updated 2026-01-14

No results posted yet for this study

Summary

This is a prospective, multicentre, unblinded, randomised, controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients with diabetes.

Conditions

Interventions

DIAGNOSTIC_TEST

NT-proBNP

NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Mark C Petrie, MbChB · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-22
Primary Completion
2025-11-30
Completion
2032-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05705869 on ClinicalTrials.gov